Prevalence of anti-insulin antibodies and its relation to severe hypoglycaemia in insulin-treated diabetic patients.
The prevalence of anti-insulin antibodies (AIABs) and their association with clinical parameters, metabolic control and severe hypoglycaemia were investigated in a geographically defined population of insulin-treated diabetic patients. Eighty per cent of the patients (479) delivered venous blood samples and answered a questionnaire on severe hypoglycaemic problems during a 12-month period. Circulating AIABs were demonstrable in 78% of the patients, being more common among those with type 1 diabetes and in long-duration patients. High levels of AIABs were also more frequent in patients in whom insulin treatment had been initiated prior to the era of highly purified insulins. The AIABs did not correlate to metabolic control, insulin dose or severe hypoglycaemia. It is concluded that AIABs is not a risk factor for severe hypoglycaemia in insulin-treated diabetic patients.
Wredling
R
R
Department of Medicine, Danderyd Hospital, Sweden.
Lins
P E
PE
Adamson
U
U
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003922:Diabetes Mellitus, Type 1 / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology* / Q000276:immunology; D007328:Insulin / Q000627:therapeutic use; D007330:Insulin Antibodies / Q000097:blood*; D008297:Male; D008875:Middle Aged; D012307:Risk Factors
D007328:Insulin; D007330:Insulin Antibodies